Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

10.19EUR
11 Dec 2017
Change (% chg)

€0.25 (+2.47%)
Prev Close
€9.94
Open
€9.98
Day's High
€10.28
Day's Low
€9.98
Volume
165,557
Avg. Vol
351,529
52-wk High
€13.68
52-wk Low
€7.65

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.46
Market Cap(Mil.): €292.94
Shares Outstanding(Mil.): 29.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

Nov 02 2017

BRIEF-‍Nicox enters research collaboration with Re-Vana Therapeutics

* ‍Nicox enters research collaboration with Re-Vana Therapeutics on its next generation of stand-alone no-donors in a novel sustained release ophthalmic formulation​

Oct 20 2017

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

Oct 10 2017

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

Oct 10 2017

BRIEF-Nicox announces licensing agreement with Eyevance

* ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES

Sep 21 2017

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​

Sep 08 2017

BRIEF-NicOx raises $31 million in private placement of shares

* ANNOUNCED ON THURSDAY A PRIVATE PLACEMENT OF SHARES TO RAISE EUR 26.25 MILLION (USD 30.97 MILLION)

Aug 18 2017

BRIEF-Nicox lists 3.5 million new shares on Euronext Paris

* NICOX SA TO LIST 3.5 MILLION NEW SHARES ON EURONEXT PARIS AS OF AUGUST 17; REFERENCE PRICE: EUR 7.5 Further company coverage: (Gdynia Newsroom)

Aug 16 2017

BRIEF-Nicox announces 26.25 million euros financing

* NICOX SA - ‍RESERVED CAPITAL INCREASE OF ORDINARY SHARES OF COMPANY TO A SPECIFIC CATEGORY OF INVESTORS​

Aug 15 2017

Earnings vs. Estimates